Experimental cocktail targets aggressive lymphoma in early trial
NCT ID NCT03321643
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a combination of the immunotherapy drug atezolizumab, two chemotherapy drugs (gemcitabine and oxaliplatin), and the targeted antibody rituximab in 24 patients with transformed diffuse large B-cell lymphoma that has come back or stopped responding to treatment. The main goals are to check safety and find the best dose. The hope is that this mix of drugs can boost the immune system to fight the cancer more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab (immunotherapy) combined with gemcitabine, oxaliplatin (chemotherapy), and rituximab (targeted antibody)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with transformed diffuse large B-cell lymphoma that has relapsed or not responded to prior therapy.
- What could go wrong
- This is a very early (Phase I) pilot study with only 24 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness, and combination therapies often carry higher risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a targeted drug boost the fight against an aggressive blood cancer?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Combination therapy targets aggressive lymphoma in CLL patients
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers